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Abstract
Despite many years of research efforts and
continued progress in the identification of urine
markers for detection of bladder cancer, none of
the markers described to date has been able to
replace cystoscopy and urine cytology, the current
gold standards for diagnosis. Here, we present a
comprehensive gel-based proteomic study in
which we have analyzed the presence and origin
of fibrinogen (FG) and its degradation products
(FDPs) in the urine of patients with and without
urothelial carcinoma (UCs), with the aim of eval-
uating the potential of two-dimensional (2D) gel
FDP profiling for detecting bladder cancer. A total
of 151 urine samples collected from patients with
UCs of varying degrees of atypia and stages of
invasion were compared with a control group
consisting of 34 healthy volunteers with no clinical
history of bladder cancer. The level and degree of
degradation of FG in the urine were determined
by 2D gel Western blotting in combination with
enhanced chemilumenscence detection. Elevated
levels of urine FG/FDPs were found in 99% of
patients bearing superficial tumors, in 97% of the
cases with early invasive disease, and in 96% of
patients with highly invasive tumors. 2D gel
profiling of urine FG/FDPs showed that the FG
chains exhibited differential susceptibility to
in situ proteolysis, with the α-chain being the
most susceptible and the γ-chain the most resis-
tant. Matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry identified pep-
tide sequence regions in several of the most
representative and common FDPs, which can be
of value for producing novel specific antibodies
to detect FG/FDPs in the urine. In addition, we
present evidence indicating that FG is not
produced by normal or malignant urothelium,
although it is present both in the stroma of malig-
nant tissue and tumor lesions. Taken together, the
data indicate that increased levels of FG/FDPs
amounts in the urine are a characteristic feature
of bladder cancer, and emphasize the value of
2D gel profiling of urine FG/FDPs for detecting
low-grade, noninvasive UCs.
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Introduction
Bladder cancer is the fifth most common
malignancy in the world, and represents the
second most common type of urological
cancer. It includes a wide spectrum of histo-
logically heterogeneous tumor types that arise
predominantly in the transitional epithelium
(urothelium) lining of the urinary bladder and
the ureters. Tumor types of the urothelium
include urothelial carcinomas (UCs), squa-
mous cell carcinomas (SCCs), adenocarcino-
mas, as well as other less frequent lesions
(1–3). UCs comprise more than 90% of the
diagnosed bladder tumors in the Western
hemisphere (4,5) and are broadly divided in
two groups—low-grade superficial papillary
lesions and high-grade lesions (carcinoma in
situ [CIS]) (1,2)—based on histological exami-
nation and clinical parameters (6,7). Super-
ficial papillary tumors (pTa, pT1) represent
approx 70% of all bladder tumors at first pre-
sentation, whereas 2–5% correspond to CIS or
flat lesions (dysplasia, atypia), and the remain-
ing display a metastasized tumor (8,9). Among
the superficial tumors, about 40% are pTa and
30% are pT1 lesions. 
Detection and characterization of bladder
cancer has relied on classic histopathological
techniques for many years. To date, cystoscopy
and urine cytology still remain the gold stan-
dards in the diagnosis of bladder cancer. 
Cystoscopy, aided by histological evaluation
of the biopsy specimens, is very effective in
identifying morphologically visible tumors,
but is an invasive procedure that causes a
great deal of discomfort to the patient. Voided
urine cytology is the oldest diagnostic test
being used in the clinic; it is noninvasive,
simple, and characterized by high specificity,
i.e., yields relatively few false-positives (10). Sev-
eral screening studies, however, have reported
low sensitivity for this test, particularly for
detecting superficial papillomas and/or low-
grade tumors (11–13). 
A number of noninvasive tests, based on
the measurement of tumor-derived molecules
that are potentially released into the urine
from malignant lesions, have recently become
available to clinicians, whereas others are
under investigation (14–22). These include: the
nuclear matrix protein 22 test (NMP-22;
Matritech, Inc.), the bladder tumor antigen 
test (BTA; Bard Diagnostic), and the fibrinogen/
fibrinogen degradation product (FG/FDPs)
test. Several comparative studies have shown
a broad variation in sensitivity and specificity
of these tests. For example, the average sensi-
tivity and specificity data published so far are
70.5 and 75.2% for NMP22; 52.3 and 84.6% for
the BTA test; and 68.3 and 77.8% for the FDP
test (14,18,19). It has been shown repeatedly
that cytology provides higher specificity but
lacks sensitivity compared to the NMP-22,
BTA, and FDP tests (14–18), underscoring the
need for a better overall test. 
In general, the urinary FDP-based tests are
simple, rapid, inexpensive, and can be per-
formed in a clinical setting. Although various
inflammatory conditions of the urinary tract
can result in detectable amounts of FDP in the
urine, several studies have shown that the
presence of FDPs is far more prevalent in 
the urine of patients with bladder cancer and
that the levels tend to be higher in patients
bearing tumors of increasing grade and
stage (23–25). This correlation may lead to
improved sensitivity for detecting more
aggressive tumors, although this issue has not
been addressed systematically. The commer-
cial Accu-Dx FDP test (the original AuraTek
FDP has been replaced with the new label,
Accu-Dx, Intracel Corp.) made use of a mon-
oclonal antibody-based immunoassay to qual-
itatively measure the levels of FG/FDPs in
the urine of patients with bladder neoplasias
(24,25). Although the initial data appeared to
be very promising, the manufacturer has
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since withdrawn the assay because of the
lack of stability and the problems associated
with the test formulation. Indeed, the sensi-
tivity and specificity of various FDP-based
tests reported so far differ widely in different
studies ranging from 27 to 100% and from 66
to 86% for sensitivity and specificity, respec-
tively (26–32). Furthermore, as with other urine-
based biochemical tests, the ability of the
FDP-based tests to detect early-stage and low-
grade tumors has not been properly established.
It is still unclear whether the low sensitivity of
urine FDP-based tests reported in several stud-
ies is caused, for example, by low affinity of the
antibody used, or by the absence/very low level
of FG/FDPs in the urine of some groups of
patients with bladder cancer. Additionally, the
origin(s) of FG/FDPs in urine of patients with
bladder cancer is/are not yet known, a fact that
hampers the improvement of urine FG/FDP-
based diagnostic.
With these concerns in mind, we present
here a comprehensive gel-based proteomic
study in which we have assessed the presence
of FG/FDPs in the urine and tumors obtained
from 151 patients bearing bladder UCs. We
show that the occurrence of FG/FDPs in
urine samples can be readily assessed by
using high-resolution two-dimensional (2D)
gel electrophoresis in combination with West-
ern blotting. Using this approach, it is possi-
ble to inspect the complexity of FG/FDPs by
displaying all fibrinogen subunit chains and
their proteolytic derivatives on a single 2D gel
immunoblot. The main aims of the study
were (1) to determine the occurrence and
identity of FG/FDPs in the urine obtained
from patients with bladder cancer bearing
UCs of various grades of atypia and stages of
invasion, (2) to investigate the intratissue
localization of fibrinogen in urinary bladder,
and (3) to identify peptide sequence regions
in the most common urine FDPs, which may
be later used as novel epitopes for designing
improved FG/FDP-based tests.
Materials and Methods
UC and Nonmalignant Tissue Samples
Tumors and other biopsies removed by
transurethral resection or from cystectomies at
the Department of Urology at the Skejby Hos-
pital (Aarhus, Denmark) were collected with
informed consent from the patient. Small pieces
of tumor tissue were dissected by the patholo-
gist and immediately transported to the labora-
tory. Tumor samples for 2D-polyacrylamide gel
electrophoresis (PAGE) analysis, having been
cleaned of clots and contaminating tissues, were
carefully dissected with the aid of a scalpel
(2–3 mm3), homogenized in a glass homoge-
nizer containing 0.2–0.3 mL of lysis solution
(9.8 M urea, 2% NP40, 2% ampholytes pH
7.0–9.0, 100 mM DTT) for 2D-PAGE analysis
and kept at –20°C until use. Tumor pieces for
cryostat sections were placed in liquid nitrogen
immediately after surgery and were kept at
–80°C. The classification and grading of UCs
were carried out according World Health Orga-
nization 1978 (33) in the Department of Urology
at the Skejby Hospital (Aarhus, Denmark). The
Scientific and Ethical Committie of Aarhus
County (Aarhus, Denmark) approved the project.
Urine Sampling and Processing 
Voided urine samples (50–100 mL) were col-
lected preoperatively (within 24 h preceding
the operation) from the same patients with UC
from whom tissue samples were obtained (see
previous section). Urines were kept at 4°C
overnight and centrifuged at 2000g for 10 min.
The supernatant was transported to the labora-
tory for further processing. Samples (20–35 mL)
were dialyzed at 4°C against distilled water
(four changes) for 24 h using membranes with
an 8-kDa cutoff. Control urine samples were
obtained from healthy volunteers at the Insti-
tute of Cancer Biology and processed as
described previously. Dialyzed urine samples
were freeze-dried and solubilized in lysis solu-
tion (9.8 M urea, 2% NP40, 2% ampholytes 
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pH 7.0–9.0, 100 mM DTT) for 2D-PAGE analy-
sis. Twenty microliters of lysis solution were
used for 1 mL of freeze-dried urine.
Collection and Analysis of Bladder Tumor
Interstitial Fluid 
Tumor interstitial fluid (TIF) collection was
performed as previously described (34). Briefly,
fresh tumor samples (0.2–0.3 g) were minced
carefully with the aid of a scalpel into small
specimens (about 1 mm3), rinsed in phosphate-
buffered saline (PBS), placed in a conical plas-
tic tube containing 0.4 mL of PBS, and
incubated for 1 h at 37°C in a humidified CO2
incubator. Following incubation, the samples
were centrifuged at 200g for 2 min followed by
centrifugation at 2000g for 20 min at 4°C. The
supernatant was lyophilized and resuspended
in 0.3 mL of lysis buffer for 2D PAGE analysis.
2D Gel Electrophoresis 
and 2D Western Blotting
Freeze-dried samples resuspended in lysis
solution were subjected to 2D PAGE as we pre-
viously described (35). About 30–40 µL of
sample were applied to the first dimension, and
several gels were run from each sample. Pro-
teins were visualized using a silver staining
procedure compatible with mass spectrometry
(MS) analysis (36). Immunoblotting was per-
formed as previously described (37) using a
polyclonal antibody (A0080, dilution 1:500)
raised against human fibrinogen obtained
from DakoCytomation (Denmark). Secondary
antibodies conjugated to a peroxidase complex
(horseradish peroxidase [HRP]-conjugated goat
anti-rabbit antibody; DakoCytomation, Denmark)
were used at a dilution of 1:1000. 2D blots were
developed using the enhanced chemilumines-
cent (ECL) assay (Amersham).
The Levels of FG/FDPs in Urine 
The presence of FG/FDPs in urine sam-
ples obtained from healthy individuals 
and from patients with UC was judged by
semiquantitative analysis of 2D Western ECL
blots. The total intensity of the FG/FDP spots
displayed on the blot was evaluated using the
PDQUEST 7.3 image software. On average, the
levels of urine FG/FDPs in patients with UC
were found to be at least two orders of magni-
tude higher than those in the normal controls.
Accordingly, immunoblot FG/FDPs patterns
were subdivided into two categories: “normal”
and “disease phenotype,” which corresponded
to low/undetectable and high levels of
FG/FDPs, respectively. To characterize the
level of FG proteolysis, the disease phenotype
group was further subdivided into moderate
(M) and high degradation patterns (H) based
on the visual assessment of a variety of low
molecular mass FDPs (less than 30 kDa).
Immunoprecipitation
Rabbit polyclonal anti-human fibrinogen
antibodies (A0080, DakoCytomation, Denmark)
were chemically crosslinked to protein A/G
Sepharose (Amersham) using dimethylpime-
limidate as a coupling agent as described else-
where (38). Lyophilized urine samples were
solubilized in a buffer containing 150 mM
NaCl, 50 mM Tris-HCl, pH 7.6, 0.1% NP40, and
incubated in presence of Ab-fibrinogen-A/G
protein sepharose beads for 12 h at 4°C.
Mass Spectrometry 
Protein spots were excised from the dry gels
followed by rehydration in water for 30 min
at room temperature. The gel pieces were
detached from the cellophane film, rinsed
twice with water, and cut into about 1-mm2
pieces with subsequent additional washes.
Proteins were “in-gel” digested with bovine
trypsin (unmodified, sequencing grade; Roche
Diagnostics, Mannheim, Germany) for 12 h as
described by Shevchenko and colleagues (39).
MS was performed on a Reflex IV matrix-
assisted laser desorption/ionization time-
of-flight (MALDI-TOF) mass spectrometer,
equipped with a Scout 384 ion source. 
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All spectra were internally calibrated using the
tryptic autodigested ions (805.417/906.505/
1153.574/1433.721/2163.057/2273.160) visible
in all spectra. Spectra were processed by
the Xmass 5.1.1 and BioTools 2.1 softwares
(Bruker Daltonik, GmbH). Searching was
performed against a comprehensive NCBInr
database, compiled from GenBank CDS
translations, PIR, SWISS-PROT, PRF, and
PDB, using the MASCOT software. No
restriction on the protein molecular mass and
taxonomy were applied. Because proteins
were recovered from gels, a number of fixed
modifications (acrylamide modified cystein,
i.e., propionamide/carbamidomethylation) as
well as variable ones (methionine oxidation
and protein N-terminus acetylation) were
included in the search parameters.
Immunohistochemistry
Fresh tumor pieces were placed in formalin
fixative and were paraffin-embedded for
archival use. Five-microliter sections were cut
from the paraffin-embedded tissue blocks and
mounted on Super Frost Plus slides (Menzel-
Gläser, Braunschweig, Germany), baked at
60°C for 60 min, deparaffinized, and rehy-
drated through graded alcohol rinses. Heat-
induced antigen retrieval was performed 
by immersing slides in 10 mM citrate buffer
(pH 6.0) and microwaving in a 750-W micro-
wave oven for 10 min. The slides were then
cooled at room temperature for 20 min and
rinsed abundantly in tap water. Nonspecific
staining of slides was blocked (10% normal
goat serum in PBS buffer) for 15 min, and
endogenous peroxidase activity quenched
using 0.3% H2O2 in methanol for 30 min. Fib-
rinogen was detected with a primary antibody
(dilution 1:500), followed by a secondary
antibody conjugated to a peroxidase complex
(HRP-conjugated goat anti-rabbit antibody;
DakoCytomation, Denmark, dilution 1:1000).
Finally, color development was done with 3,3’-
diaminobenzidine (Pierce, IL) as a chromogen
to detect bound antibody complex. Slides were
counterstained with hematoxylin. Normal goat
serum, instead of primary antibody, was used
as a negative control. Standardization of the
incubation and development times allowed
an accurate comparison of expression levels in
all cases.
Indirect Immunofluorescence
Eight-microliter cryostat sections from fro-
zen tissue were placed on round cover slips,
washed three times with PBS, and treated for 
5 min with methanol at –20°C. Cover slips
were washed several times with PBS, covered
with 20 µL of the primary antibody (A0080,
DakoCytomation, Denmark) and incubated for
60 min at 37°C in a humidified box. Next, the
formed antibody complexes were detected
with tetramethyl rhodamine isothiocyanate-
labeled secondary antibody (dilution 1:50).
Cover slips were washed extensively with PBS,
then once with distilled water, and covered
with DAKO mounting medium. Normal goat
serum, instead of primary antibody, was used
as a negative control. Sections were imaged
using either standard epilumenscence fluo-
rescence microscopy (Leica, DMRB, Deerfield,
IL) or laser scanning microscopy (Zeiss 510LSM;
Oberkochen, Germany).
Results
Specificity of the Fibrinogen Antibody 
The specificity of the fibrinogen antibody
used in this study (A0080, DakoCytomation)
was determined using normal human plasma
(source of native fibrinogen; Korda, Life 
Science), as well as a commercially available
purified fibrinogen preparation (Kordia, Life
Science). As shown in Fig. 1, the antibody reacts
with all three fibrinogen chains (α, 67 kDa; β, 58
kDa; γ, 47 kDa) yielding multiple charge trains
that correspond to posttranslational modifica-
tions. The antibody also recognized a heteroge-
neous group of proteins spots of apparent
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molecular weights of 100–120 kDa that may
represent crosslinked derivatives of soluble
fibrin polymer (Fig. 1, closed arrowheads). 
Western Blot Profiling of FG/FDPs 
in the Urine of Patients in the Control
and UC Groups
A total of 151 urine samples collected from
patients diagnosed with UC of various degrees
of atypia and stages of invasion, and 34 
control urine samples collected from healthy
volunteers with no known clinical record of
bladder malignancy were analyzed by 2D gel
immunoblotting and ECL detection using the
A0080 fibrinogen antibody (DAKO) (see Sup-
plementary Table). The gel immunoblot analy-
sis indicated that with a few exceptions (see
Supplementary Table and Table 1), the urine
samples of patients with UC exhibited much
higher levels of FG/FDPs as compared to the
normal controls (Fig. 2). In addition, the analy-
sis revealed that the degree of fibrinogen degra-
dation varied considerably among patients with
UC (Fig. 2). An overall trend of the data were
the increasing proteolytic degradation of fib-
rinogen, and the upregulation of the amount of
urinary FG/FDPs in high-grade and stage UCs
(Fig. 2B–D). Moreover, the results showed that
the fibrinogen chains display differential sus-
ceptibility to in situ proteolysis, with the α-chain
being the most susceptible and the γ-chain the
lesser. The intact form of the fibrinogen γ-chain
was detected in all the urines from patients
diagnosed with UCs, including highly invasive
stages of the disease (Fig. 2B–E), whereas the 
α-chain was more susceptible to degradation
and as a result could not be detected in most of
the superficial lesions (Fig. 2B,C).
Fig. 1. Specificity determination of the antifibrinogen polyclonal antibody (A0080, DakoCytomation) by two-
dimensional (2D) polyacrylamide gel electrophoresis (PAGE) Western blotting of human plasma proteins. Left
panel: human plasma proteins resolved by 2D PAGE and stained by silver nitrate; upper right panel: 2D
Western blot of plasma proteins; lower right panel: 2D Western blot of purified fibrinogen.The immunoblot
shown in the upper right panel corresponds to the area of the 2D gel of plasma proteins limited by the
dashed rectangle. Putative crosslinked derivatives of soluble fibrin are indicated with arrowheads.
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Table 1
Urine FG/FDP Patterns in Normal Individuals and Patients Diagnosed With UC 
of Different Grade and Stage 
FG/FDP 2D phenotype
No. of Disease phenotype Disease Normal
donors/ Normal Moderate (M) High (H) FG/FDPs FG/FDPs
Urine type patients phenotype degradation degradation phenotype (%) phenotype (%)
Normal 34 32 1 1 94%
Superficial 74 1 (1.3%) 48 (65%) 25 (33%) 99%
(GI-GIII, pTa)
Early invasive 29 1 (3.6%) 13 (45%) 15 (52%) 97%
(GI-GIII, pT1)




To assess the presence of FG/FDPs in urine
samples obtained from the control group and
the UC group, the intensities of the FG/FDP
spots were evaluated by quantitative analysis
of the 2D gel Western ECL blots (see Materials
and Methods). We found that the levels of
FG/FDPs in the UC group were on average at
least two orders of magnitude higher than
those in the control group. Based on this
observation, we subclassified the immunoblot
patterns into two categories, namely “normal”
and “disease phenotype” (Fig. 2). The disease
phenotype was further subdivided in moder-
ate (M) and high degradation patterns (H)
based on the visual assessment of a variety of
low-molecular-mass FDPs (less than 30 kDa)
as illustrated in Fig. 2B–E.
Most of the patients diagnosed with high-
grade/stage UC lesions exhibited more intense
and a higher number of degradation products
of fibrinogen in the urine as compared with
patients bearing superficial papillary tumors
(Table 1 and Fig. 2B–E). As shown in Table 1,
the proportion of patients with superficial
tumors (pTa), early invasive (pT1), and highly
invasive (pT2-4) tumors that exhibited the M
and H disease phenotypes were 65 and 33%,
43 and 54%, and 18 and 77%, respectively. 
The analysis of the 34 normal urine samples
revealed very weak or even undetectable levels
of FG/FDPs (normal phenotype) (Table 1 and
Fig. 2A), although in two individuals we
observed elevated levels of FG/FDPs similar
to those that are characteristic of the disease
phenotype (false-positives). One of them,
however, was later found to suffer from
chronic cystitis.
Origin of FG/FDPs in the Urine
The presence of traces of fibrinogen in the
urine of healthy donors has recently been
reported by Pieper and colleagues (40). The
origin of the peptides is unknown at present
as, under normal physiological conditions,
only small amounts of proteins reach the
urinary bladder as a result of the plasma fil-
tration process that take place in the kidney
glomeruli. In the case of patients with bladder
cancer, however, it is likely that the presence
of plasma proteins in the urine may be caused
by, in part, bleeding caused by tumor growth.
To address this possibility, we analyzed 
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(by means of 2D PAGE and silver staining) sev-
eral diseased urine samples that showed high
levels of FG/FDPs. As shown in Fig. 3, two
urine samples (UC1779-1 and 1756-1) displayed
much higher levels of hemoglobin β-chain,
indicating the presence of blood in the sample,
whereas others (UC 1776-1 and 1774-1) failed
to show any detectable levels of this protein
(Fig. 3), implying that fibrinogen and its degra-
dation derivatives originate mainly from the
tumor and/or the tumor microenvironment. 
Immunostaining of tumor sections with the
fibrinogen antibody showed that fibrinogen,
and perhaps FDPs, are present in the surround-
ing stroma of both nonmalignant (Fig. 4A,C)
and tumor lesions (Fig. 4E), but not in the
epithelial cells themselves. The latter was con-
firmed indirectly by in vitro experiments that
showed no traces of FG/FDPs in several
urothelial cell lines (RT112, T24, HU609, and
HU961, data not shown). Clusters of fibrin/
fibrinogen were also visible in the cavities of
capillaries decorated by the anti-factor VIII-
related antigen (AbF8/86, DAKO) (compare
Fig. 4C,D). Immunohistochemical analysis of
paraffin-embedded sections of several UC
lesions further indicated that the immunore-
activity for FG/FDPs is considerably higher 
in the stroma of high grade/stage tumors 
(Fig. 5A–D). Moreover, 2D gel blot analysis of
whole tumor lysates showed comparable
levels of degradation products as observed in
the corresponding urine (Fig. 6, compare tumor
1291 and urine 1291; Fig. 6 compare tumor 1789
and urine 1789). In addition, immunoblot and
MS analysis of the TIF that bathes the tumor
microevironment (34,41) revealed the presence
of FG/FDPs in TIF recovered from a few 
UCs (Fig. 7).
Identification of Specific Urinary 
FDPs by Immunoprecipitation 
and MALDI-TOF
Although the 2D gel patterns of FG/FDPs
in the urine samples of patients with UC
varied significantly from patient to patient
(Fig. 2), some of the FDP spots were detected
in most of the disease urines examined.
Because these FG peptides may serve as a
potential source for producing more specific
antibodies for detecting FG/FDPs, as well as
for developing more effective and reliable
FG/FDP-based diagnostic tests, we character-
ized several of them using MS. To facilitate 
the identification, peptides were first enriched
by immunoprecipitation using protein A/G
Sepharose beads bound to anti-fibrinogen
antibodies (A0080, DAKO) (Fig. 8). Several
prominent FDP peptides indicated with circles
in Fig. 8 were excised from the dry silver-
stained gel and analyzed by MALDI-TOF. The
identity of these FDP peptides is given in
Table 2. 
Discussion
To gain a better understanding of the
origin of FG/FDP in the urine, and to evalu-
ate their potential value for detecting bladder
cancer, we performed a detailed gel-based
proteomic analysis of FG/FDPs present in
the urine of 151 patients diagnosed with UCs
of various degrees of atypia and stages of
invasion. Our data showed that the repertoire
of fibrinogen components in the urine is very
complex and highly variable from patient to
patient, a fact that may hamper the accurate
detection of FG/FDPs in samples using
enzyme-linked immunosorbent assay-based
immunoassays. 2D PAGE portrays all fib-
rinogen components with high resolution in a
single 2D gel image and provides a conve-
nient and reliable method for monitoring
FG/FDPs. Of the 151 patients diagnosed with
UCs, 147 individuals (97%) showed increased
levels of FG/FDPs in the urine, whereas the
rest (3%) either lacked or exhibited very low
levels of these components.
Previous studies have shown that FDPs are
more accurate for detecting high-grade inva-
sive diseases as compared to early stage
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Fig. 4. Indirect immunofluorescence analysis of nonmalignant areas of the bladder and the corresponding
urothelial carcinoma specimens obtained from the same patient. Clusters of fibrinogen and its degradation
derivatives were detected by staining with antifibrinogen polyclonal antibody (A0080, DAKO) (A,C,E). Blood
capillaries were revealed by staining with an anti-factorVIII-related antigen (F8/86, DAKO) that is specific for
endothelial cells (D). Tissue structure in sections was decorated by staining with the monomeric cyanine
nucleic acid stain TO-PRO3 (B,F) specific for nuclei.
tumors (25,27,30,32). Our proteomic studies,
however, revealed that the percentage of
positive detections, when comparing patients
with superficial, early invasive, and highly
invasive tumors, was comparable (99, 97, and
96%, respectively; Table 1) in all three groups.
As a whole, these data indicate that elevated
levels of FDPs in the urine are a characteristic
feature of bladder cancer, and that measuring
the levels of urinary FG/FDPs holds great
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Fig. 5. Immunohistochemistry of cryostat sections from nonmalignant samples and urothelial carcinomas of var-
ious stages and grades. Immunohistochemistry was carried out using a fibrinogen polyclonal antibody (A0080,
DAKO) followed by counter-staining with Hematoxilin.
promise for detecting low-grade, noninvasive
tumors. 
Analysis of the urine samples from 34
healthy volunteers showed that FG/FDPs are
either absent or present at very low levels.
Interestingly, elevated levels of FG/FDPs (false-
positives) were detected in two of the control
samples; one of which was from a woman that
we later found to be suffering from chronic 
cystitis. These results are not unexpected as it
is well known that conditions, such as inflam-
mation, toxicity, renal cancer (affecting the 
filtration process in the kidney glomeruli and
tubuli), and urinary tract stones may lead to
increased levels of plasma proteins in the urine
(42,43).
So far, the proposed mechanisms by which
FG/FDPs may access the urine of patients with
bladder neoplasias are unclear (30). Thus, it has
been postulated that fibrinogen circulating in the
blood may reach the urine as a result of bleeding
caused by tumor invasion. Even though the
occasional bleeding of invasive tumors may con-
tribute to the accumulation of FG/FDPs into the
bladder cavity, our results showed that patients
with superficial UCs had a considerable amount
of FG/FDPs in the urine, despite the fact that
there were no signs of bleeding. Presently, it is
widely accepted that fibrin(ogen) is not normally
present outside the blood vessels, although it
can easily reach the perivascular tissues during
wounding and in some malignancies (44,45).
It has been also suggested that increased per-
meability of the tumor cell membrane permits
the direct transduction of FG/FDPs into the
urine (29,30,46). Our results, however, showed
that fibrinogen and its derivatives are not pro-
duced by normal or by malignant urothelium.
More importantly, we found that the stroma 
of nonmalignant areas contain considerable
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Fig. 6.Two-dimensional gel Western blot profiling of FG/FDPs from urine samples (patients 1291 and 1789) and
the corresponding tumor specimens.
Fig. 7.Tumor interstitial fluid proteins from UC 1748-1 separated by two-dimensional (2D) isoelectrofocusing
(IEF) polyacrylamide gel electrophoresis and stained with silver nitrate (left panel).The corresponding 2D gel
Western FG/FDPs pattern is shown on the right panel.
amounts of FG/FDPs, most likely derived from
passive or active transport of some plasma pro-
teins through the capillary vessels. Moreover,
the deposition of FG/FDPs seems to increase in
high-grade and -stage tumors supporting the
notion that fibrin/fibrinogen may facilitate
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Fig. 8. Mass spectrometry of FDP peptides. The identity of several FDP spots was determined by matrix-
assisted laser desorption/ionization time-of-flight after immunoprecipitation of FG/FDPs with the fibrinogen
antibody bound to sepharose-protein A.
tumor stroma formation by mechanisms that
are perhaps analogous to wound repair
(45,47,48). Thus, it is known that malignant
cells produce the angiogenic factor (vascular
endothelial growth factor) that increases
vessel wall permeability in the tumor micro-
vasculature resulting in leakage of plasma
proteins such as plasminogen, clotting factors,
and fibrinogen into the extravascular space
(49–51). Recently, we described the protein
characterization of a near fluid (the TIF)
that perfuses breast carcinomas and that is
composed of more than 1000 proteins—either
secreted, shed by membrane vesicles like exo-
somes, or leaked as a result of cell death—
produced by the complex network of cell
types that make up the tumor microenviron-
ment (34,41). 2D Western blot analysis of the
TIF recovered from UCs of various grades
and stages of invasion confirmed the presence
of FG/FDPs in the tumor microenvironment. 
The presence of FG/FDPs in the extracellular
matrix of nonmalignant samples may help to
interpret the relatively high levels of FG/FDPs
Table 2
MALDI-TOF Identification of Several FDPs Presented in the Urine 
of the Most Patients With Developed Bladder UCs 
No. of peptides MASCOT Sequence 
FDP spota Identification matched score coverage
1 Fibrinogen β-chain, 19 227 152–491 aa
precursor
2 Fibrinogen β-chain, 7 98 295–491 aa
precursor
3 Fibrinogen β-chain, 9 85 152–491 aa
precursor
4 Fibrinogen β-chain, 9 105 161–491 aa
precursor
5 Fibrinogen γ-chain, 6 78 1–301 aa
precursor
aThe FDP spots are indicated with their corresponding numbers in Fig. 8.
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Patients With UCs of Various Histopathological Grade of Atypia and Tumor Stage
IHC classification Urine FG/FDPs
Count Tumor IDa (grade/stage)b phenotypec Age Genderd
Superficial UCs (GI-III,Ta) 
1 62-9 GIII,Ta Moderate 70 M 
2 81-5 GIII,Ta Moderate 65 M 
3 150-7 GII,Ta Moderate 67 M 
4 154-3 GII,Ta High 76 M 
5 192-9 GII,Ta Moderate 64 M 
6 217-9 GII,Ta High 51 M 
7 269-2 GII,Ta Moderate 62 M 
8 335-6 GI,Ta Moderate 77 F 
9 381-1 GII,Ta Moderate 77 F 
10 387-6 GI,Ta Moderate 72 M 
11 450-16 GII,Ta Moderate 83 M 
12 455-1 GII,Ta Moderate 41 M 
13 521-1 GI,Ta Moderate 27 M
14 532-8 GII,Ta Moderate 44 M
15 542-13 GII,Ta Moderate 65 F
16 716-2 GIII,Ta High 42 M
17 763-13 GII,Ta High 66 M
18 775-1 GIII,Ta Moderate 70 M
19 776-1 G0,Ta Moderate 54 M
20 793-1 GI,Ta Moderate 67 M
21 807-1 G?,Ta Moderate 74 M
22 825-10 GIII,Ta Moderate 75 M
23 829-3 GII,Ta High 63 F
24 835-1 GII,Ta High 70 M
25 854-3 GII,Ta High 71 F
26 854-4 GII,Ta High 72 F
27 916-1 GI,Ta High 51 F
28 916-6 GI,Ta Moderate 53 F
29 925-1 GII,Ta High 62 M
30 925-3 GII,Ta Moderate 63 M
31 929-1 GI,Ta Moderate 70 M
32 956-2 GIII,Ta High 75 F
33 968-1 GII,Ta Moderate 71 M
34 969-1 GII,Ta normal 60 F
35 995-1 GII,Ta Moderate 53 F
36 997-1 GII,Ta Moderate 52 M
37 968-1 GII,Ta Moderate 71 M
38 1009-1 GII,Ta High 70 M
39 1017-1 GIII,Ta High 79 M
40 1020-2 GIII,Ta Moderate 77 M
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(Continued)
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41 1024-2 GIII,Ta Moderate 63 M
42 1045-1 GII,Ta Moderate 69 M
43 1058-3 GII,Ta Normal 67 M
44 1060-1 GII,Ta Moderate 59 M
45 1066-1 GIII,Ta High 80 M
46 1079-1 GII,Ta Moderate 57 M
47 1084-1 GI,Ta Moderate 58 M
48 1092-1 GIII,Ta High 66 M
49 1094-2 GIII,Ta Moderate 49 M
50 1118-1 GII,Ta High 59 M
51 1145-1 GII,Ta High 79 M
52 1146-1 GII,Ta High 53 M
53 1174-1 G0,Ta Moderate 54 M
54 1206-1 GI,Ta Moderate 62 M
55 1216-1 GII,Ta Moderate 73 M
56 1241-2 GII,Ta Moderate 70 M
57 1246-1 GI,Ta High 81 M
58 1250-1 GI,Ta High 65 F
59 1282-2 GII,Ta High 77 M
60 1325-1 GII,Ta Moderate 54 F
61 1587-3 GII,Ta Moderate 94 M
62 1707-2 G0,Ta Moderate 69 M
63 1732-3 G0,Ta Moderate 77 M
64 1762-1 GII,Ta High 75 F
65 1764-1 GII,Ta Moderate 68 M
66 1772-1 G?,Ta Moderate 71 M
67 1776-1 G0,Ta High 69 M
68 1785-2 GII,Ta High 72 M
69 1786-1 GII,Ta Moderate 60 M
70 1787-1 GII,Ta High 65 M
71 1790-1 GI,Ta Moderate 38 F
72 1791-2 GI,Ta High 65 M
73 1802-1 GII,Ta High 64 F
74 1805-1 GII,Ta Moderate 80 M
Early invasive Ucs (GI-III,T1)
75 195-11 GIII,T1 High 69 M
76 320-2 GIII,T1 Moderate 69 M
77 347-10 GIII,T1 High 79 M
78 351-5 GIII,T1 Moderate 78 M
79 444-5 GIII,T1 Moderate 84 M
80 485-1 G?,T1 High 59 F
81 729-4 GIII,T1 Moderate 89 F
(Continued)
IHC classification Urine FG/FDPs
Count Tumor IDa (grade/stage)b phenotypec Age Genderd
Supplementary Table (Continued)
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82 744-1 GIII,T1 Moderate 76 M
83 757-1 GII,T1 Moderate 69 M
84 760-1 GIII,T1 Moderate 72 M
85 785-1 GIII,T1 Moderate 71 M
86 847-1 GIII,T1 Normal 82 M
87 936-1 GIII,T1 High 78 F
88 950-1 GIII,T1 High 81 M
89 967-1 GIII,T1 Moderate 67 M
90 1036-1 GIII,T1 Moderate 79 M
91 1049-1 GII,T1 High 82 M
92 1056-1 GIII,T1 High 58 F
93 1075-1 GIII,T1 High 72 F
94 1098-2 GIII,T1 High 83 F
95 1121-1 GIII,T1 High 42 M
96 1191-1 GIV,T1 High 76 M
97 1191-2 GIII,T1 Moderate 76 M
98 1311-1 GIII,T1 High 74 M
99 1270-1 GIII,T1 High 82 M
100 1177-1 GIII,T1 Moderate 56 M
101 1779-1 GIII,T1 High 67 M
102 1783-1 GIII,T1 High 78 M
103 1785-1 GIII,T1 Moderate 72 M
Highly invasive UCs (GII-IV,T2-4)
104 116-3 GIII,T2-4 High 80 M
105 163-2 GIV,T2-4 High 71 M
106 195-14 GIII,T2-4 Moderate 74 M
107 376-9 GIII,T2-4 High 64 F
108 389-1 GIV,T2-4 High 76 M
109 475-T1 GIII,T2-4 High 69 M
110 715-4 GIII,T2-4 Moderate 73 M
111 752-5 GIII,T2-4 High 53 M
112 788-1 GIII,T2-4 High 78 M
113 816-5 GIII,T2-4 Moderate 76 M
114 817-1 GIII,T2-4 High 69 M
115 846-3 GIII,T2-4 Moderate 72 F
116 852-1 GIII,T2-4 High 82 M
117 864-1 GIII?,T2-4 High 51 M
118 868-1 GIII,T2-4 High 60 F
119 902-1 GIV,T2-4 High 65 F
120 905-1 GII,T2-4 High 53 M
121 1015-1 GIII,T2-4 High 58 M
122 1016-1 GIII,T2-4 High 70 M
(Continued)
IHC classification Urine FG/FDPs
Count Tumor IDa (grade/stage)b phenotypec Age Genderd
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123 1017-3 GIII,T2-4 Low 79 M
124 1026-1 GIV,T2-4 High 64 F
125 1027-2 GIII,T2-4 Normal 69 F
126 1035-1 GIV,T2-4 High 76 M
127 1068-1 GIII,T2-4 Normal 57 F
128 1169-1 GIV,T2-4 High 82 M
129 1170-1 GIV,T2-4 High 65 M
130 1203-1 GIV,T2-4 High 56 M
131 1205-1 GIV,T2-4 High 78 M
132 1218-1 GIII,T2-4 High 53 M
133 1243-1 GIII,T2-4 High 56 M
134 1271-1 GIII,T2-4 Moderate 58 M
135 1271-2 GIII,T2-4 High ? ?
136 1291-1 GIV,T2-4 High 48 M
137 1304-1 GIV?,T2-4 High 84 F
138 1316-1 GIII,T2-4 High 62 M
139 1322-1 GIV,T2-4 High 51 F
140 1664-2 GIII,T2-4 Moderate 79 M
141 1664-3 GIV,T2-4 High 79 M
142 1672-3 GIII,T2-4 High 66 M
143 1707-1 GIII,T2-4 High 69 M
144 1756-1 GIII,T2-4 High 90 M
145 1770-1 GIII,T2-4 High 76 F
146 1774-1 GIII,T2-4 Moderate 48 M
147 1777-1 GIII,T2-4 High 64 M
148 1780-1 GIV,T2-4 High 63 M
149 1789-1 GIII,T2-4 High 62 M
150 1798-1 GIII,T2-4 High 62 F
151 1803-1 GIII,T2-4 Moderate 56 M
aTumor ID indicates a patient number (XXXX-) and a presentation number (-Y) that are separated with a dash. 
bUCs were classified according WHO 1978 (33). 
cFG/FDPs immunoblot phenotypes were determined and classified as described in Materials and Methods.
dM, male; F, female.
IHC classification Urine FG/FDPs
Count Tumor IDa (grade/stage)b phenotypec Age Genderd
Supplementary Table (Continued)
that we observed in urine samples obtained
from patients with superficial noninvasive UCs.
At present, however, it is not clear how
FG/FDPs and other TIF components reach the
urine, although recent studies have shown that
the interstitial fluid pressure is elevated in
tumors (52). Because of the high permeability of
the tumor vessels to fluids and plasma proteins,
the microvascular pressure leads to interstitial
hypertension in tumors that is associated with
the development of the tumor vasculature (53).
It is then possible that the tumor interstitial
hypertension (52) may contribute to the release
of extravascular proteins into the bladder cavity. 
Future attempts to develop more accurate
test to measure the levels of FG/FDPs in the
urine should focus on the preparation of more
specific antibody probes. Our data showed
05_Gromov.qxd  11/21/06  3:14 PM  Page 62
Volume 2, 2006 ________________________________________________________________ Clinical Proteomics
Proteomic Analysis of Urinary FDPs____________________________________________________________ 63
that α-, β-, and γ-chains of FG exhibited dif-
ferent susceptibilities to proteolysis in situ and
that the FG 2D gel degradation patterns varied
considerably from patient to patient depend-
ing on the grade and stage of the tumors 
(Fig. 2). Consequently, for future peptide–
antigen design it is a crucial to select FG frag-
ments that are most representative of those
present in the urine samples of patients with
UC. Toward this goal, we detected several FDP
spots that were present in all the urines dis-
playing the disease phenotype (Figs. 2 and 8).
The sequence coverage obtained from the
MALDI-TOF data showed that FDPs corre-
sponding to spots 1, 2, 3, and 4 (Fig. 8) were
derived from the fibrinogen β-chain and con-
tained C-terminal fragments covering amino
acids 152 to 491, 161 to 491, and 295 to 491,
respectively (Table 2). Spot 5, on the other
hand, corresponded to a N-terminal fragment
of fibrinogen γ-chain that covered amino acids
1 to 301. Our results also indicated that the 
γ-chain of fibrinogen was the most resistant to
proteolytic degradation in situ in line with
prior in vitro experiments that showed differ-
ential susceptibility of the lysyl and arginyl
residues in the α-, β-, and γ-chains of purified
FG to plasmin degradation (54). Taken together,
these data suggest that the fibrinogen γ-chain
as well as C-terminal fragment of the β-chain
(152–491 aa) may be the most suitable candi-
dates for a peptide-antigen design strategy for
developing highly-specific antibodies for a uri-
nary FG/FDP-based test.
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